SOUTH SAN FRANCISCO, Calif.,
May 8, 2019 /PRNewswire/
-- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will announce its
first quarter 2019 financial results after market close on
Wednesday, May 15, 2019. Following
the release, Titan management will host a conference call at
4:30 p.m. EDT / 1:30 p.m. PDT to review the financial results and
discuss business developments in the period.
The conference call will be hosted by Sunil Bhonsle, President and CEO; Kate Beebe DeVarney, Ph.D., Executive Vice
President and Chief Scientific Officer; Dane Hallberg, Executive Vice President and
Chief Commercial Officer; Brian
Crowley, Vice President of Finance; and Marc Rubin, M.D., Executive Chairman.
The live conference call may be accessed by dialing
1-888-317-6003 (U.S.) or 1-412-317-6061 (international) and
providing passcode 1059834. The call will also be broadcast live
and archived on Titan's website at
www.titanpharm.com/news/events.
About Titan Pharmaceuticals
Titan Pharmaceuticals,
Inc. (NASDAQ:TTNP), based in South San
Francisco, CA, is a commercial stage company developing
proprietary therapeutics with its ProNeura™ long-term, continuous
drug delivery technology. The company's lead product is
Probuphine® (buprenorphine) implant, a novel and
long-acting formulation of buprenorphine for the long-term
maintenance treatment of opioid dependence. Approved by the U.S.
Food and Drug Administration in May
2016, Probuphine is the first and only commercialized
treatment of opioid dependence to provide continuous,
around-the-clock blood levels of buprenorphine for six months
following a single procedure. The ProNeura technology also has the
potential to be used in developing products for treating other
chronic conditions such as Parkinson's disease and hypothyroidism,
where maintaining consistent, around-the-clock blood levels of
medication may benefit the patient and improve medical outcomes.
For more information about Titan, please visit
www.titanpharm.com.
Forward-Looking Statements
This press
release may contain "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Such statements include, but are
not limited to, any statements relating to our product
commercialization and development programs and any other statements
that are not historical facts. Such statements involve risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock price. Factors that could
cause actual results to differ materially from management's current
expectations include those risks and uncertainties relating to the
commercialization of Probuphine, the regulatory approval process,
the development, testing, production and marketing of our drug
candidates, patent and intellectual property matters and strategic
agreements and relationships. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
CONTACTS:
Sunil Bhonsle
President & CEO
(650) 244-4990
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-to-release-first-quarter-2019-financial-results-on-may-15--conference-call-to-follow-300846864.html
SOURCE Titan Pharmaceuticals, Inc.